SEARCH

SEARCH BY CITATION

References

  • 1
    Jessup M, Brozena S. Heart failure. N Engl J Med. 2003; 348: 20072018.
  • 2
    McMurray J, Pfeffer M. Heart failure. Lancet. 2005; 365: 18771889.
  • 3
    Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation. 2006; 114: 838854.
  • 4
    Tsuyuki RT, McDonald MA. Angiotensin receptor blockers do not increase risk of myocardial infarction. Circulation. 2006; 114: 855860.
  • 5
    Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BMW. Renin–angiotensin system and cardiovascular risk. Lancet. 2007; 369: 12081219.
  • 6
    Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 20222031.
  • 7
    ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. New Engl J Med. 2008; 358: 15471559.
  • 8
    Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, De Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. LIFE Study Group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359: 9951003.
  • 9
    Tenhunen O, Soini Y, Ilves M, Rysä J, Tuukkanen J, Serpi R, Pennanen H, Ruskoaho H, Leskinen H. p38 Kinase rescues failing myocardium after myocardial infarction: evidence for angiogenic and anti-apoptotic mechanisms. FASEB J. 2006; 20: E1276E1286.
  • 10
    Sutton MG, Sharpe N. Left ventricular remodelling after myocardial infarction: pathophysiology and therapy. Circulation. 2000; 101: 29812988.
  • 11
    Wei S, Chow L T C, Sanderson JE. Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction. J Am Coll Cardiol. 2000; 36: 276281.
  • 12
    Jain M, Liao R, Ngoy S, Whittaker P, Apstein CS, Eberli FR. Angiotensin II receptor blockade attenuates the deleterious effects of exercise training on post-MI ventricular remodelling in rats. Cardiovasc Res. 2000; 46: 6672.
  • 13
    Oh H, Bradfute SB, Gallardo TD, Nakamura T, Gaussin V, Mishina Y, Pocius J, Michael LH, Behringer RR, Garry DJ, Entman ML, Schneider MD. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci USA. 2003; 100: 1231312318.
  • 14
    Jiang X, Gurel O, Mendiaz EA, Stearns GW, Clogston CL, Lu HS, Osslund TD, Syed RS, Langley KE, Hendrickson WA. Structure of the active core of human stem cell factor and analysis of binding to its receptor kit. EMBO J. 2000; 19: 31923203.
  • 15
    Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N, Frunwald F, Aicher A, Urbich C, Martin H, Hoelzer D, Dimmeler S, Zeiher AM. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation. 2002; 106: 30093017.
  • 16
    Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, Homma S, Edwards NM, Itescu S. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 2001; 7: 430436.
  • 17
    Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, Kasahara H, Rota M, Musso E, Urbanek K, Leri A, Kajstura J, Nadal-Ginard B, Anversa P. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003; 114: 763776.
  • 18
    Dimmeler S, Burchfield J, Zeiher AM. Cell-based therapy of myocardial infarction. Arterioscler Thromb Vasc Biol. 2008; 28: 208216.
  • 19
    Urbanek K, Torella D, Sheikh F, De Angelis A, Nurzynska D, Silvestri C, Beltrami A, Bussani R, Beltrami AP, Quaini F, Bolli R, Leri A, Kajstura J, Anversa P. Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure. Proc Natl Acad Sci USA. 2005; 102: 86928697.
  • 20
    Fazel S, Cimini M, Chen L, Li S, Angoulvant D, Fedak P, Verma S, Weisel RD, Keating A, Li R-K. Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J Clin Invest. 2006; 116: 18651877.
  • 21
    Lehrke S, Mazhari R, Durand DJ, Zheng M, Bedja D, Zimmet JM, Schuleri KH, Chi AS, Gabriel-son KL, Hare JM. Aging impairs the beneficial effect of granulocyte colony-stimulating factor and stem cell factor on post-myocardial infarction remodeling. Circ Res. 2006; 99: 553560.
  • 22
    Dahlke MH, Larsen SR, Rasko JEJ, Schlitt HJ. The biology of CD45 and its use as a therapeutic target. Leuk Lymphoma. 2004; 45: 229236.
  • 23
    Brown DC, Gatter KC. Ki67 protein: the immaculate deception? Histopathology. 2002; 40: 211.
  • 24
    Cruickshank JM. The beta 1 hyperselectivity in beta-blocker treatment. J Cardiovasc Pharmacol. 1995; 25(Suppl 1): S35S46.
  • 25
    Ayach BB, Yoshimitsu M, Dawood F, Sun M, Arab S, Chen M, Higuchi K, Siatskas C, Lee P, Lim H, Zhang J, Cukerman E, Stanford WL, Medin JA, Liu PP. Stem cell factor receptor induces progenitor and natural killer cell-mediated cardiac survival and repair after myocardial infarction. Proc Natl Acad Sci USA. 2006; 103: 23042309.
  • 26
    Smart N, Riley PR. Stem cell movement. Circ Res. 2008; 102: 11551168.
  • 27
    Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, Rovner A, Ellis SG, Thomas JD, DiCorleto PE, Topol EJ, Penn MS. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet. 2003; 362: 697703.
  • 28
    Palmer JN, Hartogensis WE, Patten M, Fortuin FD, Long CS. Interleukin-1β induces cardiac myocyte growth but inhibits cardiac fibroblast proliferation in culture. J Clin Invest. 1995; 95: 25552564.
  • 29
    Hwang M-W, Matsumori A, Furukawa Y, Ono K, Okada M, Iwasaki A, Hara M, Miyamoto T, Touma M, Sasayama S. Neutralization of interleukin-1β in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling. J Am Coll Cardiol. 2001; 38: 15461553.
  • 30
    Teiger E, Dam T-V, Richard L, Wisnewsky C, Tea B-S, Gaboury L, Tremblay J, Schwartz K, Hamet P. Apoptosis in pressure overload-induced heart hypertrophy in the rat. J Clin Invest. 1996; 97: 28912897.
  • 31
    LaFramboise WA, Bombach KL, Dhir RJ, Muha N, Cullen RF, Pogozelski AR, Turk D, George JD, Guthrie RD, Magovern JA. Molecular dynamics of the compensatory response to myocardial infarct. J Mol Cell Cardiol. 2005; 38: 103117.
  • 32
    Kajstura J, Cigola E, Malhotra A, Li P, Cheng W, Meggs LG, Anversa P. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol. 1997; 29: 859870.
  • 33
    El-Adawi H, Ding L, Tramontano A, Smith S, Mascareno E, Ganguly K, Castillo R, El-Sherif N. The functional role of the JAK-STAT pathway in post-infarction remodelling. Cardiovasc Res. 2003; 57: 129138.
  • 34
    Gonzalez GE, Palleiro J, Monroy S, Perez S, Rodriquez M, Masucci A, Gelpi RJ, Morales C. Effects of the early administration of losartan on the functional and morphological aspects of postmyocardial infarction ventricular remodeling in rabbits. Cardiovascular Pathol. 2005; 14: 8895.
  • 35
    Dedkov EI, Christensen LP, Weiss RM, Tomanek RJ. Reduction of heart rate by chronic beta1-adrenoceptor blockade promotes growth of arterioles and preserves coronary perfusion reserve in postinfarcted heart. Am J Physiol Heart Circ Physiol. 2005; 288(6): H2684H2693.
  • 36
    Boyle AJ, Schuster M, Witkowski P, Xiang G, Seki T, Way K, Itescu S. Additive effects of endo-thelial progenitor cells combined with ACE inhibition and β-blockade on left ventricular function following acute myocardial infarction. J Renin Angiotensin Aldosterone Syst 2005; 6: 3337.
  • 37
    Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000; 52: 1134.
  • 38
    Escobar E, Rodriquez-Reyna TS, Arrieta O, Sotelo J. Angiotensin II, cell proliferation and an-giogenesis regulator: biologic and therapeutic implications in cancer. Curr Vasc Pharmacol. 2004; 2: 385399.
  • 39
    Rivera E, Arrieta O, Guevara P, Rojo-Duarte A, Sotelo J. AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma. Br J Cancer. 2001; 85(9): 13961399.
  • 40
    De Boer RA, Pinto YM, Suurmeijer AJH, Pokharel S, Scholtens E, Humler M, Saavedra JM, Boomsma F, Van Gilst WH, Van Veldhuisen DJ. Increased expression of cardiac angiotensin II type 1 (AT1) receptors decreases myocardial microvessel density after experimental myocardial infarction. Cardiovasc Res. 2003; 57: 434442.
  • 41
    Munzenmaier DH, Greene AS. Chronic angiotensin II AT1 receptor blockade increases cerebral cortical microvessel density. Am J Physiol Heart Circ Physiol. 2006; 290: H512H516.
  • 42
    Levy BI. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Circulation. 2004; 109: 813.
  • 43
    Schneider MD, Lorell BH. A T 2, judgment day. Which angiotensin receptor is the culprit in cardiac hypertrophy? Circulation. 2001; 104: 247248.
  • 44
    Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ. 2004; 329: 12481249.
  • 45
    Yu Y, Fukuda N, Yao E-H, Matsumoto T, Kobayashi N, Suzuki R, Tahira Y, Ueno T, Matsumoto K. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension. Am J Hypertens. 2008; 21: 7277.
  • 46
    Leri A, Kajstura J, Anversa P, Frishman WH. Myocardial regeneration and stem cell repair. Curr Probl Cardiol. 2008; 33: 91153.
  • 47
    Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990; 81: 11611172.
  • 48
    Doughty RN, Whalley GA, Walsh HA, Gamble GD, Lopez-Sendon J, Sharpe N, for the CAPRICORN Echo Substudy Investigators. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation. 2004; 109: 201206.
  • 49
    Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau J-L, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Eng J Med. 2003; 349(20): 18931906.
  • 50
    Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet. 2005; 360: 752760.